BioLineRx Ltd.
BioLineRx Ltd. is listed today as BioLineRx Ltd.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $4 M | Private placement after listing | $2 to $10 million | options | SEC | |
| May 2020 | $4 M | Private placement after listing | $2 to $10 million | options | SEC | |
| May 2020 | $9 M | Private placement after listing | $2 to $10 million | options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
BioLineRx Ltd. chose not to state its revenue in its newest notice of a funding round (Sep 2026).
SEC Form D · Sep 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2026
That is all the official record says: BioLineRx Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of BioLineRx Ltd. are on record.
Investors#
No investor of BioLineRx Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding BioLineRx Ltd. shares, as of Sep 30, 2026.
- Armistice Capital, LLC$1 M—
- Citadel Advisors LLC$0 M—
- Susquehanna International Group, LLP$0 M—
- Stifel Financial Corp$0 M—
- Renaissance Technologies LLC$0 M—
- Rhumbline Advisers$0 M—
- Wells Fargo & Company/mn$0 M—
- Nemes Rush Group LLC$0 M—
- Tower Research Capital LLC (TRC)$0 M—
- UBS Group AG$0 M—
- NewEdge Advisors, LLC$0 M—
- Osaic Holdings, Inc.$0 M—
- BFC Planning, Inc.$0 M—
- SBI Securities Co., Ltd.$0 M—
- Danske Bank A/s$0 M—
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Ella A. Sorani | Chief Development Officer | Sep 2026 |
| Mali A. Zeevi | Chief Financial Officer | Sep 2026 |
| Philip A. Serlin | Chief Executive Officer | Sep 2026 |
| Abi A. Vainstein-Haras | Executive officer | Jun 2020 |
| Aharon A. Schwartz | Director | Sep 2026 |
| Avraham A. Molcho | Director | Sep 2026 |
| BJ A. Bormann | Director | Sep 2026 |
| Gal A. Cohen | Director | Sep 2026 |
| Rami A. Dar | Director | Sep 2026 |
| Raphael A. Hofstein | Director | Sep 2026 |
| Sandra A. Panem | Director | Sep 2026 |
| Shaoyu A. Yan | Director | Sep 2026 |
| Aharon Schwartz | Director | Jun 2020 |
| Avraham Jean Molcho | Director | Jun 2020 |
| Barbara Jean Bormann | Director | Jun 2020 |
| Michael J. Anghel | Director | Jun 2020 |
| Nurit J. Benjamini | Director | Jun 2020 |
| Raphael Jean Hofstein | Director | Jun 2020 |
| Sandra Jean Panem | Director | Jun 2020 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.